Evaluate Discovery
NEWSLETTER
Welcome to Evaluate Discovery, a round up of our most-read content this month.
Featured Report: World Preview 2024
Have you downloaded your copy of the World Preview 2024 report? It’s our annual dive into the latest forecasts for the pharma market and if you’ve not read it yet, you can find it here. Featuring expert analysts and tonnes of data, it’s a must-read for anyone who needs to understand the direction of the market, from key players to top pipeline projects.
Welcome to Evaluate Discovery, a round up of our most-read content this month.
Have you downloaded your copy of the World Preview 2024 report?
Have you downloaded your copy of the World Preview 2024 report? It’s our annual dive into the latest forecasts for the pharma market and if you’ve not read it yet, you can find it here. Featuring expert analysts and tonnes of data, it’s a must-read for anyone who needs to understand the direction of the market, from key players to top pipeline projects.
Report
Billion Dollar Blueprint: The Journey to Blockbuster Status
Learn about the role that indications play, the typical timeline to reach blockbuster status, and the advantages of developing drugs internally versus outsourcing.
e-book
EVALUATING: Radiopharmaceuticals
Radiopharmaceuticals have lit up – sparking more interest than even ADCs, with significant M&A activity in recent months. Check out the latest science and most interesting players
REPORT
The 2024 Freshness Index: Who Needs To Freshen Up?
Which Big Pharma companies need to address an aging pipeline? We’ve crunched the patent expiry numbers to rank the players who need to freshen up.
on-demand webinar
Are Orphan Drugs Losing Their Sparkle?
Orphans’ bright gloss is beginning to dull after a decade of massive growth. Watch our on-demand webinar to discover the reasons behind this shift and what the future may hold
Blog
Navigating the Complex World of Business Development
2024 has the potential to be a year full of partnering opportunities, driven by the much-discussed patent cliff as some of the biggest-selling drugs in history are set to lose exclusivity by 2028.
BLOG
Meet the Team: Andrew Ward
in recent news, Evaluate acquired J+D Forecasting, a leading provider of forecasting solutions. Take a few minutes to meet Andrew Ward, Head of Implementation Team to find out about his love of forecasting.
upcoming webinar
AI and ML in Pharma - Redefining the Forecasting Landscape
JULY 31, 2024 – 3:00PM BST | 10:00AM EST
Join leading experts from J+D Forecasting as they shed light on the transformative potential of AI and ML in pharmaceutical forecasting, enabling more precise predictions, improved decision-making, and strategic guidance for the industry.
